Research brings hope of new treatment for asthma patients resistant to …News-Medical.netNew research from Japan brings hope of a new treatment for asthma patients resistant to corticosteroids. In a study published today in the journal Nature Communic…
|
Multiple antenatal corticosteroids posed no increased risk for death
Healio Multiple courses of prenatal corticosteroid therapy taken by pregnant women did not affect the risk for death or disability in their children, according to data published in JAMA Pediatrics. “Because of a lack of strong conclusive evidence of short … |
|
Fetal exposure to mycophenolic acid products may increase risk of birth defects
News-Medical.net Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at … Kidney Transplant Rejection Drugs Tied to Pregnancy Risks in StudyU.S. News & World Report Stopping transplant drugs before conception benefits fetusScience Codex |
Kidney Transplant Rejection Drugs Tied to Pregnancy Risks in StudyHealthDayThe study included 163 female transplant patients who discontinued mycophenolic acid products prior to conception and 114 who conceived while taking the anti-rejection drugs. …..
Corticosteroids effectively treated patients on anti-TNF-a therapy with …HealioPatients being treated with anti-tumor necrosis factor-alpha drugs who developed psoriasiform eruptions achieved partial to complete resolution of lesions after topical co…
Curis, Debiopharm Start Phase I Study Of Debio 0932 With EverolimusNASDAQ(RTTNews.com) – Curis, Inc.( CRIS ), and Debiopharm Group Tuesday announced the start of a Phase I dose-finding study of Debio 0932, a heat shock protein 90 inhibitor in combinati…
Curis, Debiopharm Start Phase I Study Of Debio 0932 With EverolimusRTT NewsCuris, Inc.(CRIS: Quote), and Debiopharm Group Tuesday announced the start of a Phase I dose-finding study of Debio 0932, a heat shock protein 90 inhibitor in combination with e…
Curis (CRIS), Debiopharm Initiate Debio 0932 Phase IStreetInsider.com (subscription)This dose escalation study is designed to determine the safety and maximum tolerated dose of Debio 0932 in combination with everolimus, in previously treated patients w…
Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding …GlobeNewswire (press release)This dose escalation study is designed to determine the safety and maximum tolerated dose of Debio 0932 in combination with everolimus, in previo…
|
STENTYS to Present First Results of Sirolimus-Eluting Self-Apposing(R) Stent …
Wall Street Journal STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing(R) Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial will be … |